Bristol-Myers Squibb Rights
CELG.RT
22 hedge funds and large institutions have $303K invested in Bristol-Myers Squibb Rights in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
61% more capital invested
Capital invested by funds: $189K → $303K (+$114K)
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$28.6K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$3.33K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$622 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$548 |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
+$444 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$47K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.11K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$56 |
CELG.RT Hedge Fund Activity: Q3 2021 in Review
22 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q3 2021, worth a combined $303K — up 61% from $189K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CELG.RT positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $28.6K. The largest seller was Maven Securities, exiting entirely with an estimated $47K sold.
- 22 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q3 2021, up from 21 in Q2 2021.
- Funds reported $303K of Bristol-Myers Squibb Rights stock for Q3 2021, up 61% quarter-over-quarter.
- 2 funds opened new Bristol-Myers Squibb Rights positions in Q3 2021 and 1 closed out, a net change of +1 holder.
- The largest Bristol-Myers Squibb Rights buyer in Q3 2021 was Boothbay Fund Management, an estimated $28.6K added.
- The largest Bristol-Myers Squibb Rights seller in Q3 2021 was Maven Securities, an estimated $47K sold.
Based on aggregated 13F filings for Q3 2021.